Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25022292 | 0.80 | ALOX15 (0.37) | CHRNB2CHRNA4CHRNB4ALOX15CYP19A1 | |
| SCHEMBL12410088 | 0.80 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CYP19A1CHRNA3 | |
| SCHEMBL4292777 | 0.78 | CYP19A1 (0.49) | CYP19A1CA1ALDH1A1ADRA2AADRA1A | |
| SCHEMBL1517765 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3CA1 | |
| SCHEMBL29061599 | 0.75 | BLM (0.52) | CHRNB2CHRNA4CHRNB4ALOX15CA1 | |
| SCHEMBL12410080 | 0.75 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CYP19A1CHRNA3 | |
| SCHEMBL14823561 | 0.74 | PTPN1 (0.43) | ALOX15CYP19A1DNM1ADRA2AADRA1A | |
| SCHEMBL1050907 | 0.74 | BLM (0.50) | ALOX15CYP19A1ADRA2AADRA1APTPN1 | |
| SCHEMBL9480399 | 0.74 | DNM1 (0.56) | CHRNB2CHRNA4CYP19A1CA1ALDH1A1 | |
| SCHEMBL14273817 | 0.74 | BLM (0.50) | ALOX15CYP19A1ADRA2AADRA1APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | CHRNB2 4633/4885CHRNA4 4837/4885CHRNB4 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.